Tacalcitol in the treatment of psoriasis vulgaris: The Spanish experience

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue 4, 2005, Pages 414-417

  Lecha, M ^a   Mirada, A ^b   Lopez S ^c   Artes M ^c  

^a HOSPITAL CLÍNIC   (Spain)

^b Laboratorios Isdin   (Spain)

^c Pharma Research   (Spain)

Author keywords

Compliance; Psoriasis; Tacalcitol; Tolerability

Indexed keywords

ANTIPSORIASIS AGENT; DITHRANOL DERIVATIVE; EMOLLIENT AGENT; PETROLATUM; RETINOID; SALICYLIC ACID; STEROID; TACALCITOL; TAR; VITAMIN D DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL OBSERVATION; CLINICAL TRIAL; COHORT ANALYSIS; CONSULTATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOLOGY; DESQUAMATION; DISEASE DURATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; EXPERIENCE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; MEDICAL SPECIALIST; MULTICENTER STUDY; OINTMENT; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS VULGARIS; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SKINFOLD THICKNESS; SPAIN; SYMPTOM; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; DERMATOLOGIC AGENTS; DIHYDROXYCHOLECALCIFEROLS; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PROSPECTIVE STUDIES; PSORIASIS; SEVERITY OF ILLNESS INDEX; SPAIN; TREATMENT OUTCOME;

EID: 21744454177     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2005.01099.x     Document Type: Article

References (9)

1. Ferrándiz C. Dermatosis eritematoescamosas (I). Psoriasis. Eritrodermia. In: Ferrándiz C, ed. Dermatología Clínica. Mosby, Madrid, 1996: 149-156.
2. Christophers E, Mrowietz U. Epidermis: Disorders of persistent inflammation, cell kinetics, and differentiation. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI & Fitzpatrick TB, eds. Dermatology in General Medicine. McGraw-Hill, Maidenhead, 1999: 495-521.
3. Van der Kerkhof PCM, Werfel T, Haustein UF et al. Tacalcitol ointment in the treatment of psoriasis vulgaris: a multicentre, placebo-controlled, double-blind study on efficacy and safety. Br J Dermatol 1996; 135: 758-765.
4. Ribera M, Casanova JM. Tacalcitol. Un nuevo derivado de la vitamina D3 eficaz para el tratamiento de la psoriasis. Piel 1999; 14: 118-121.
5. Peters DC, Balfour JA. Tacalcitol. Drugs 1997; 54(2): 265-271.
6. Berth-Jones J. The emergence of vitamin D as a first-line treatment for psoriasis. J Dermatol Treat 1998; 9 (Suppl. 3): S13-S18.
7. Van de Kerkhof PCM, Van de Vleuten CJM, Gerritsen MJP et al. Long-term efficacy and safety of once-daily treatment of chronic plaque psoriasis with tacalcitol ointment. Eur J Dermatol 1997; 7: 421-425.
8. Scarpa C. Tacalcitol ointment is an efficacious and well tolerated treatment for psoriasis. J Eur Acad Dermatol Venereol 1996; 6: 142-146.
9. Veien NK, Bjerke JR, Rossmann-Ringdahl I, Jakobsen HB. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol 1997; 137: 581-586.